The HNRNPDL Knockout A-549 Polyclonal Cells are a genetically engineered polyclonal population generated from the A-549 human lung adenocarcinoma cell line using CRISPR/Cas9 technology to disrupt the HNRNPDL gene. This polyclonal knockout model eliminates functional HNRNPDL protein expression, providing a reliable loss-of-function system for investigating RNA-binding protein-mediated regulatory mechanisms. Unlike clonal isolates, the polyclonal format reduces cell line adaptation artifacts and ensures broad representation of edited alleles, facilitating robust and reproducible experimental outcomes.
The parental A-549 cell line is a well-established model of human lung adenocarcinoma derived from an alveolar epithelial carcinoma. It carries a homozygous KRAS G12S-activating mutation and retains wild-type p53, a genetic signature representative of a significant subset of non-small cell lung cancers. A-549 cells exhibit adherent epithelial morphology and are routinely employed in oncology research for studies on oncogene addiction, apoptosis, and drug resistance.
HNRNPDL is a multifunctional RNA-binding protein that regulates pre-mRNA alternative splicing, mRNA stability, and telomere maintenance. It interacts with core splicing regulators such as HNRNPA1, SRSF1, and U2AF2, and cooperates with the telomerase catalytic subunit TERT and spliceosomal snRNPs. Upstream, HNRNPDL activity is modulated by PI3K/AKT signaling and SP1-driven transcription. Its downstream targets include CD44, where it controls exon v6 inclusion, BCL2L1 (encoding BCL-X), where it promotes the anti-apoptotic BCL-XL isoform, and telomeric repeat-containing RNA (TERRA), which it binds to influence telomere length. CRISPR-mediated knockout ablates these interactions, causing widespread splicing alterations and telomeric dysfunction.
In A-549 cells, loss of HNRNPDL specifically impairs the splicing of transcripts involved in cell adhesion, survival, and proliferation. The shift in CD44 isoforms may alter invasive potential, while skewed BCL-X isoform production can enhance sensitivity to apoptotic stimuli. Concurrent disruption of TERRA processing compromises telomere integrity, potentially synergizing with KRAS-driven replicative stress and p53-mediated checkpoint responses. This system thus enables dissection of how splicing dysregulation and telomere instability contribute to lung adenocarcinoma pathogenesis.
This knockout tool supports a wide array of experimental workflows, including transcriptome-wide splicing analysis by RNA-seq, targeted isoform quantification via RT-qPCR, and protein-level validation through western blotting. Functional assays such as MTT cell viability, Annexin V apoptosis detection, and telomere length measurement by qFISH or TRF can be combined with RIP-seq or splicing minigene reporters to map direct HNRNPDL targets. The cells also serve in screening splicing-modulatory compounds, modeling limb-girdle muscular dystrophy type 1G, and identifying splicing-based cancer biomarkers. For technical support or purchasing inquiries, contact Ascent Research.
